A Phase 1 interventional study of Sotorasib in Healthy Participants, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to compare the pharmacokinetics (PK) of sotorasib dose A administered orally as 3 tablets (test) to sotorasib dose A administered orally as 8 tablets (reference).
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered sotorasib dose A orally in the following order: * Treatment A - as 3 tablets (test 1) * Treatment B - as 8 tablets (reference) * Treatment C - as 3 tablets (test 2)
Drug: Sotorasib
Participants will be administered sotorasib dose A orally in the following order: * Treatment B - as 8 tablets (reference) * Treatment A - as 3 tablets (test 1) * Treatment C - as 3 tablets (test 2)
Drug: Sotorasib
Oral tablet
Also known as: AMG 510
Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma pharmacokinetic (PK) parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Number of Participants Who Experienced a Treatment-emergent AE (TEAE)
An AE is any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment. Any abnormal clinical laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., 12-lead electrocardiogram or vital signs measurements), including those that worsen from baseline, that are considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) were considered AEs.
Time frame: Day 1 to Day 9
Food Effect: Cmax of Sotorasib
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Food Effect: AUClast of Sotorasib
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Food Effect: AUCinf of Sotorasib
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Overall, 145 participants were enrolled in the study in the United States between 16 August 2021 and 18 February 2022.
| Milestone | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC |
|---|---|---|---|---|
| Started | 66 | 66 | 6 | 7 |
| Administered treatment a | 66 | 0 | 6 | 0 |
| Administered treatment b | 0 | 66 | 0 | 7 |
| Completed | 63 | 65 | 6 | 7 |
| Not completed | 3 | 1 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 | 0 |
| Milestone | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC |
|---|---|---|---|---|
| Started | 63 | 65 | 6 | 7 |
| Administered treatment a | 0 | 65 | 0 | 7 |
| Administered treatment b | 63 | 0 | 6 | 0 |
| Completed | 63 | 64 | 6 | 7 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Milestone | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC |
|---|---|---|---|---|
| Started | 0 | 0 | 6 | 7 |
| Administered treatment c | 0 | 0 | 6 | 7 |
| Completed | 0 | 0 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma pharmacokinetic (PK) parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
| ng/mL | Treatment A | Treatment B |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B | 6650 ± 41.3 | 6540 ± 37.3 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
| h*ng/mL | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B | 27800 ± 51.1 | 27500 ± 41.6 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.
| h*ng/mL | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B | 28600 ± 48.1 | 27700 ± 41.5 |
An AE is any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment. Any abnormal clinical laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., 12-lead electrocardiogram or vital signs measurements), including those that worsen from baseline, that are considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) were considered AEs.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants Who Experienced a Treatment-emergent AE (TEAE) | 8 | 10 | 0 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
| ng/mL | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Food Effect: Cmax of Sotorasib | 6390 ± 34.6 | 6790 ± 28.9 | 6400 ± 19.0 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
| h*ng/mL | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Food Effect: AUClast of Sotorasib | 23900 ± 40.8 | 26100 ± 31.1 | 34500 ± 19.2 |
Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.
| h*ng/mL | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Food Effect: AUCinf of Sotorasib | 23500 ± 41.0 | 26500 ± 30.3 | 34700 ± 19.2 |
Collected over Day 1 to Day 9. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/145 (0%) | 0/145 (0%) | 8/145 (5.5%) |
| Treatment B | 0/145 (0%) | 0/145 (0%) | 10/145 (6.9%) |
| Treatment C | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/145 | 0/145 | 0/13 |
| VomitingGastrointestinal disorders | 2/145 | 1/145 | 0/13 |
| HeadacheNervous system disorders | 2/145 | 1/145 | 0/13 |
| LymphadenitisBlood and lymphatic system disorders | 0/145 | 1/145 | 0/13 |
| VertigoEar and labyrinth disorders | 1/145 | 0/145 | 0/13 |
| Abdominal painGastrointestinal disorders | 1/145 | 0/145 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 1/145 | 0/145 | 0/13 |
| Faeces discolouredGastrointestinal disorders | 0/145 | 1/145 | 0/13 |
| Influenza like illnessGeneral disorders | 0/145 | 1/145 | 0/13 |
| Covid-19Infections and infestations | 1/145 | 0/145 | 0/13 |
The safety population included all participants who received at least 1 dose of sotorasib and had at least 1 postdose safety assessment.
| Age, Categorical(Participants) | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 66 | 66 | 6 | 7 | 145 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC | Total |
|---|---|---|---|---|---|
| Female | 7 | 6 | 1 | 1 | 15 |
| Male | 59 | 60 | 5 | 6 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 27 | 31 | 4 | 1 | 63 |
| Not Hispanic or Latino | 39 | 35 | 2 | 6 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 26 | 30 | 0 | 4 | 60 |
| White | 39 | 34 | 6 | 3 | 82 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Aug 2021 to primary completion in Feb 2022, 6 months.
Results were first posted in Sep 2023, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib